Metastatic Non-Small Cell Lung Cancer Market 2034: Epidemiology Data, Drug Approval, Forecast by DelveInsight

DelveInsight’s Metastatic Non-Small Cell Lung Cancer Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, June 12, 2024 /EINPresswire.com/ -- DelveInsight’s “Metastatic Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Metastatic Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Metastatic Non-Small Cell Lung Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Metastatic Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Non-Small Cell Lung Cancer Market Forecast

Some of the key facts of the Metastatic Non-Small Cell Lung Cancer Market Report:
The Metastatic Non-Small Cell Lung Cancer market size was valued ~21 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In November 2023, AUGTYRO (repotrectinib, BristolMyers Squibb) received approval from the US FDA for use in adults with locally advanced or metastatic ROS1-positive NSCLC, especially in instances with brain metastases.
In October 2023, Pfizer's BRAFTOVI + MEKTOVI combination was approved by the US FDA for the treatment of metastatic NSCLC with BRAF V600E mutation.
On October 3, 2023, Takeda decided to voluntarily withdraw EXKIVITY from the market following the failure of a confirmatory trial.
In October 2023, Belgian pharmaceutical firm Janssen, a subsidiary of Johnson & Johnson, has disclosed results from the Phase III MARIPOSA-2 clinical study evaluating Rybrevant (amivantamab-vmjw) treatments in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This open-label, randomized trial investigated the safety and effectiveness of two Rybrevant treatment protocols in combination with chemotherapy, administered with and without lazertinib.
In January 2023, Novocure announced that the LUNAR study, assessing the safety and effectiveness of Tumor Treating Fields (TTFields) alongside standard treatments for stage 4 Metastatic Non-Small Cell Lung Cancer (NSCLC) after progression on or following platinum-based therapy, successfully achieved its primary goal.
Currently, the non-small cell lung cancer (NSCLC) treatment landscape is primarily shaped by checkpoint inhibitors like KEYTRUDA and OPDIVO. However, in the market for EGFR-positive NSCLC, we anticipate that third-generation EGFR inhibitors such as AstraZeneca’s TAGRISSO will play a dominant role in terms of market size.
In the United States in 2023, there were an estimated 202,600 new cases of lung cancer, with around 114,300 cases occurring in men and approximately 88,400 cases in women. Small cell lung cancer (SCLC) accounts for about 10–15% of all lung cancers, while non-small cell lung cancer (NSCLC) comprises approximately 80–85% of cases.
In terms of age-specific impact, individuals aged 65 years and older are more affected by non-small cell lung cancer (NSCLC) compared to those under the age of 65. In 2023, there were approximately 138,700 cases of NSCLC diagnosed in individuals aged 65 years and above in the United States.
The overall number of new cases of NSCLC across the 7MM was approximately 526,800 cases in 2022, with projections indicating a rise throughout the forecast period from 2024 to 2034. Statistics suggest that the United States has the highest incidence of NSCLC, followed by Japan, Germany, and the UK.
In the EU4 countries, Germany recorded the highest number of new cases of NSCLC, estimated at around 56,000, while Spain had the lowest incidence, with approximately 26,000 cases reported in 2022.
Key Metastatic Non-Small Cell Lung Cancer Companies: Daiichi Sankyo/AstraZeneca, Gilead Sciences, BieGene, GlaxoSmithKline, DualityBio, Latin American Cooperative Oncology Group, Mirati Therapeutics Inc., Eli Lilly and Company, Fox Chase Cancer Center, Merck Sharp & Dohme LLC, BeiGene, NeoImmuneTech, Iovance Biotherapeutics, Inc, Sanofi, Hutchison Medipharma Limited, OncoC4, Inc., Sichuan Kelun Pharmaceutical, Arcus Biosciences, Inc., and others
Key Metastatic Non-Small Cell Lung Cancer Therapies: DatopotamabDeruxtecan(Dato-DXd), TRODELVY, Ociperlimab, JEMPERLI, ZEJULA, DB-1305, Amivantamab, AZD2936, Adagrasib, LY3537982, Nivolumab, Pembrolizumab/Vibostolimab, Tislelizumab, efineptakin alfa, LN-145, SAR408701, Dostarlimab, Savolitinib, Gotistobart, Trastuzumab deruxtecan, SKB264, Domvanalimab, and others
The Non-Small Cell Lung Cancer epidemiology based on gender analyzed that males are affected more in case of PD-L1 NSCLC as compared to females.
The Metastatic Non-Small Cell Lung Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Non-Small Cell Lung Cancer pipeline products will significantly revolutionize the Metastatic Non-Small Cell Lung Cancer market dynamics.

Metastatic Non-Small Cell Lung Cancer Overview
Metastatic non-small cell lung cancer (NSCLC) is a type of lung cancer that has spread from the primary tumor in the lungs to other parts of the body. NSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. The term "metastatic" indicates that the cancer cells have traveled through the bloodstream or lymphatic system to distant organs or tissues, such as the brain, bones, liver, or adrenal glands.

Get a Free sample for the Metastatic Non-Small Cell Lung Cancer Market Report:
https://www.delveinsight.com/report-store/metastatic-non-small-cell-lung-cancer-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Non-Small Cell Lung Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic Non-Small Cell Lung Cancer Epidemiology Segmentation:
The Metastatic Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Metastatic Non-Small Cell Lung Cancer
Prevalent Cases of Metastatic Non-Small Cell Lung Cancer by severity
Gender-specific Prevalence of Metastatic Non-Small Cell Lung Cancer
Diagnosed Cases of Episodic and Chronic Metastatic Non-Small Cell Lung Cancer

Download the report to understand which factors are driving Metastatic Non-Small Cell Lung Cancer epidemiology trends @ Metastatic Non-Small Cell Lung Cancer Epidemiology Forecast

Metastatic Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Metastatic Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metastatic Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Non-Small Cell Lung Cancer Therapies and Key Companies
DatopotamabDeruxtecan(Dato-DXd): Daiichi Sankyo/AstraZeneca
TRODELVY: Gilead Sciences
Ociperlimab: BieGene
JEMPERLI: GlaxoSmithKline
ZEJULA: GlaxoSmithKline
DB-1305: DualityBio
Amivantamab: Latin American Cooperative Oncology Group
AZD2936: AstraZeneca
Adagrasib: Mirati Therapeutics Inc.
LY3537982: Eli Lilly and Company
Nivolumab: Fox Chase Cancer Center
Pembrolizumab/Vibostolimab: Merck Sharp & Dohme LLC
Tislelizumab: BeiGene
efineptakin alfa: NeoImmuneTech
LN-145: Iovance Biotherapeutics, Inc
SAR408701: Sanofi
Dostarlimab: GlaxoSmithKline
Savolitinib: Hutchison Medipharma Limited
Gotistobart: OncoC4, Inc.
Trastuzumab deruxtecan: Daiichi Sankyo
SKB264: Sichuan Kelun Pharmaceutical
Domvanalimab: Arcus Biosciences, Inc.

Metastatic Non-Small Cell Lung Cancer Market Strengths
NSCLC has emerged as a target indication of interest in oncology in the last decade. The focus of most trials in NSCLC in recent years has been in the metastatic setting as monotherapy or in combination with chemotherapy and other targeted agents.

Metastatic Non-Small Cell Lung Cancer Market Opportunities
Front-line NSCLC represents a large market,currently only being dominated by anti-PD 1 drugs and anti-PD-1 + CTx combination, leaving a significant opportunity for therapy beyond antiPD1 to deliver higher clinical benefit.

Scope of the Metastatic Non-Small Cell Lung Cancer Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Metastatic Non-Small Cell Lung Cancer Companies: Daiichi Sankyo/AstraZeneca, Gilead Sciences, BieGene, GlaxoSmithKline, DualityBio, Latin American Cooperative Oncology Group, Mirati Therapeutics Inc., Eli Lilly and Company, Fox Chase Cancer Center, Merck Sharp & Dohme LLC, BeiGene, NeoImmuneTech, Iovance Biotherapeutics, Inc, Sanofi, Hutchison Medipharma Limited, OncoC4, Inc., Sichuan Kelun Pharmaceutical, Arcus Biosciences, Inc., and others
Key Metastatic Non-Small Cell Lung Cancer Therapies: DatopotamabDeruxtecan(Dato-DXd), TRODELVY, Ociperlimab, JEMPERLI, ZEJULA, DB-1305, Amivantamab, AZD2936, Adagrasib, LY3537982, Nivolumab, Pembrolizumab/Vibostolimab, Tislelizumab, efineptakin alfa, LN-145, SAR408701, Dostarlimab, Savolitinib, Gotistobart, Trastuzumab deruxtecan, SKB264, Domvanalimab, and others
Metastatic Non-Small Cell Lung Cancer Therapeutic Assessment: Metastatic Non-Small Cell Lung Cancer current marketed and Metastatic Non-Small Cell Lung Cancer emerging therapies
Metastatic Non-Small Cell Lung Cancer Market Dynamics: Metastatic Non-Small Cell Lung Cancer market drivers and Metastatic Non-Small Cell Lung Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Metastatic Non-Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Non-Small Cell Lung Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Metastatic Non-Small Cell Lung Cancer market share @ Metastatic Non-Small Cell Lung Cancer Treatment Market

Table of Contents
1. Metastatic Non-Small Cell Lung Cancer Market Report Introduction
2. Executive Summary for Metastatic Non-Small Cell Lung Cancer
3. SWOT analysis of Metastatic Non-Small Cell Lung Cancer
4. Metastatic Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance
5. Metastatic Non-Small Cell Lung Cancer Market Overview at a Glance
6. Metastatic Non-Small Cell Lung Cancer Disease Background and Overview
7. Metastatic Non-Small Cell Lung Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic Non-Small Cell Lung Cancer
9. Metastatic Non-Small Cell Lung Cancer Current Treatment and Medical Practices
10. Metastatic Non-Small Cell Lung Cancer Unmet Needs
11. Metastatic Non-Small Cell Lung Cancer Emerging Therapies
12. Metastatic Non-Small Cell Lung Cancer Market Outlook
13. Country-Wise Metastatic Non-Small Cell Lung Cancer Market Analysis (2020–2034)
14. Metastatic Non-Small Cell Lung Cancer Market Access and Reimbursement of Therapies
15. Metastatic Non-Small Cell Lung Cancer Market Drivers
16. Metastatic Non-Small Cell Lung Cancer Market Barriers
17. Metastatic Non-Small Cell Lung Cancer Appendix
18. Metastatic Non-Small Cell Lung Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here